Thymic epithelial neoplasms: Updates on diagnosis, staging, biology and management in France;Tumeurs épithéliales thymiques: Actualités dans la prise en charge en France

Bulletin du Cancer

Volumn 99, Issue 11, 2012, Pages 1045-1055

  Hadoux, Julien ^a   Girard, Nicolas ^b   Besse, Benjamin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b LOUIS PRADEL HOSPITAL   (France)

Author keywords

RYTHMIC network; Targeted therapy; Thymic carcinoma; Thymic epithelial neoplasm; Thymoma

Indexed keywords

CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; HISTOPATHOLOGY; HUMAN; LYMPHATIC SYSTEM TUMOR; MEDICAL EDUCATION; MEDICAL RESEARCH; MOLECULARLY TARGETED THERAPY; PATIENT INFORMATION; PRACTICE GUIDELINE; REVIEW; THYMIC EPITHELIAL NEOPLASM; THYMOMA; THYMUS CANCER;

EID: 84871119192     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1659     Document Type: Article

References (53)

1. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC, eds. Pathology and genetics of tumors of the lung, pleura, thymus and heart. In : World Health Organization classification of tumors. Lyon : International Agency for Research on Cancer (IARC) Press, 2004.
2. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48 : 2485-92. (Pubitemid 12228012)
3. Bretel J. Staging and preliminary results of the Thymic Tumour Study Group. In : Sarrazin R, Vrousos C, Vincent F, eds. 7th Cancer Research Workshop. Basel (Swiss) : Karger, 1989.
4. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94 : 624-32. (Pubitemid 34132289)
5. Chen G, Marx A, Chen WH, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002; 95 : 420-9. (Pubitemid 34787609)
6. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 1995 ; 60 : 908-13 (discussion 914).
7. Levasseur P, Menestrier M, Gaud C, et al. Thymomas and associated diseases. Apropos of a series of 255 surgically treated thymomas. Rev Mal Respir 1988; 5 : 173-8.
8. Cowen D, Richaud P, Mornex F, et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération nationale des centres de lutte contre le cancer. Radiother Oncol 1995; 34 : 9-16.
9. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. J Thorac Cardiovasc Surg 1996; 112 : 376-84. (Pubitemid 26301849)
10. Ruffié P, Gory-Delabaere G, Fervers B, Lehmann M, Regnard JF, Resbeut M. Standards, options and recommendations (SOR) for clinical care of malignant thymoma. Groupe de travail SOR. Bull Cancer 1999; 86 : 365-84. (Pubitemid 29230828)
11. Exbrayat C, Colonnat M, Menegoz F. Descriptive epidemiology of thymoma. In : Sarrazin R, Vrousos C, Vincent F, eds. 7th Cancer Research Workshop. Basel (Swiss) : Karger, 1989.
12. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010; 5(10 suppl. 4) : S260-5.
13. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008; 22 : 509-26. (Pubitemid 351726408)
14. Evoli A, Minicuci GM, Vitaliani R, et al. Paraneoplastic diseases associated with thymoma. J Neurol 2007; 254 : 756-62. (Pubitemid 47012452)
15. Zhang H, Lu n, Wang M, Gu X, Zhang D. Postoperative radiotherapy for stage I thymoma: a prospective randomized trial in 29 cases. Chin Med J 1999; 112 : 136-8.
16. Fernandes AT, Shinohara ET, Guo M, et al. The role of radiation therapy in malignant thymoma: a surveillance, epidemiology, and end results database analysis. J Thorac Oncol 2010; 5 : 1454-60.
17. Ogawa K, Uno T, Toita T, et al. Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. Cancer 2002; 94 : 1405-13. (Pubitemid 34212633)
18. Curran Jr. WJ, Kornstein MJ, Brooks JJ, Turrisi 3rd. AT. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. J Clin Oncol 1988; 6 : 1722-7. (Pubitemid 19089051)
19. Monden Y, Nakahara K, Iioka S, et al. Recurrence of thymoma: clinicopathological features, therapy, and prognosis. Ann Thorac Surg 1985; 39 : 165-9. (Pubitemid 15166962)
20. Singhal S, Shrager JB, Rosenthal DI, LiVolsi VA, Kaiser LR. Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg 2003; 76 : 1635-41 (discussion 1641-2).
21. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg 2003 ; 76 : 878-84 (discussion 884-5).
22. Chen YD, Feng QF, Lu HZ, et al. Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys 2010; 78 : 1400-6.
23. Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma has little impact on survival. Cancer 2009; 115 : 5413-20.
24. Uematsu M, Yoshida H, Kondo M, et al. Entire hemithorax irradiation following complete resection in patients with stage II-III invasive thymoma. Int J Radiat Oncol Biol Phys 1996; 35 : 357-60. (Pubitemid 26158759)
25. Sugie C, Shibamoto Y, Ikeya-Hashizume C, et al. Invasive thymoma: postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination. J Thorac Oncol 2008; 3 : 75-81.
26. Riely GJ, Huang J. Induction therapy for locally advanced thymoma. J Thorac Oncol 2010; 5(10 suppl. 4) : S323-6.
27. Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 1999; 17 : 2737-44. (Pubitemid 29415230)
28. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990; 8 : 1419-23. (Pubitemid 20252315)
29. Girard N, Shen R, Guo T, et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009; 15 : 6790-9.
30. Girard N. Thymic tumors: relevant molecular data in the clinic. J Thorac Oncol 2010; 5(10 suppl. 4) : S291-5.
31. Ionescu DN, Sasatomi E, Cieply K, Nola M, Dacic S. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005; 103 : 630-6.
32. Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ. Phase II study of gefitinib treatment in advanced thymic malignancies. ASCO Meet Abstr 2005; 23(16 suppl.) : 7068.
33. Christodoulou C, Murray S, Dahabreh J, et al. Response of malignant thymoma to erlotinib. Ann Oncol 2008; 19 : 1361-2. (Pubitemid 351911975)
34. Pedersini R, Vattemi E, Lusso MR, Mazzoleni G, Ebner H, Graiff C. Erlotinib in advanced well-differentiated thymic carcinoma with overexpression of EGFR: a case report. Tumori 2008; 94 : 849-52.
35. Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007; 12 : 757-61. (Pubitemid 46852818)
36. Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A. Response of thymoma to cetuximab. Lancet Oncol 2007; 8 : 449-50. (Pubitemid 46621774)
37. Ströbel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004; 350 : 2625-6. (Pubitemid 38758557)
38. Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PCW. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009; 4 : 1270-3.
39. Sasaki H, Yukiue H, Kobayashi Y, et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001; 31 : 1038-40. (Pubitemid 33141297)
40. Tomita M, Matsuzaki Y, Edagawa M, et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 2002; 124 : 493-8.
41. Bedano PM, Perkins S, Burns M, et al. A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. ASCO Meet Abstr 2008; 26(15 suppl.) : 19087.
42. Loehrer Sr. PJ, Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 1997; 15 : 3093-9. (Pubitemid 27377501)
43. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004; 44 : 369-79. (Pubitemid 38609446)
44. Kunitoh H, Tamura T, Shibata T, et al. A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). Br J Cancer 2010; 103 : 6-11.
45. Berruti A, Borasio P, Gerbino A, et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999; 81 : 841-5. (Pubitemid 29504694)
46. Grassin F, Paleiron N, André M, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol 2010; 5 : 893-7.
47. Loehrer Sr. PJ, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001; 91 : 2010-5. (Pubitemid 32476364)
48. Loehrer Sr. PJ, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994; 12 : 1164-8. (Pubitemid 24173929)
49. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996; 14 : 814-20.
50. Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011; 29 : 2060-5.
51. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. ASCO Meet Abstr 2006; 24(18 suppl.) : 7079.
52. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993; 16 : 342-5. (Pubitemid 23217895)
53. Loehrer Sr. PJ, Wang W, Johnson DH, Aisner SC, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial. J Clin Oncol 2004; 22 : 293-9. (Pubitemid 41095094)